Vincerx Pharma Stock (NASDAQ:VINC)

Forecast Ownership Financials Chart

Previous Close

$0.27

52W Range

$0.22 - $19.88

50D Avg

$0.88

200D Avg

$7.16

Market Cap

$1.34M

Avg Vol (3M)

$1.14M

Beta

1.39

Div Yield

VINC Company Profile

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

May 27, 2020

Website

VINC Performance

VINC Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-31.46M	$-42.61M	$-73.57M
Net Income	$-30.07M	$-40.16M	$-57.16M
EBITDA	$-31.46M	$-42.61M	$-68.67M
Basic EPS	$-15.85	$-1.89	$-2.72
Diluted EPS	$-15.85	$-1.89	$-2.72

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
CHRS	Coherus BioSciences, Inc.
SRZN	Surrozen, Inc.
PCSA	Processa Pharmaceuticals, Inc.
SPRO	Spero Therapeutics, Inc.
SNTI	Senti Biosciences, Inc.
BOLT	Bolt Biotherapeutics, Inc.
LYRA	Lyra Therapeutics, Inc.
LVTX	LAVA Therapeutics N.V.
RZLT	Rezolute, Inc.
TARA	Protara Therapeutics, Inc.
MNPR	Monopar Therapeutics Inc.
XOMA	XOMA Corporation
BCAB	BioAtla, Inc.
APLT	Applied Therapeutics, Inc.
STTK	Shattuck Labs, Inc.